Key facts
- Interius BioTherapeutics’s last known valuation is $350.0M (Oct 2025).
- It has raised $169.6M across 4 recorded rounds; the latest was Later Stage VC ($51.4M) in May 2024.
- Notable investors include Osage University Partners, Cormorant Asset Management, Pfizer Ventures, Logos Capital, Knollwood Investment Advisory — 20 tracked in total.
- Interius BioTherapeutics has filed 4 Form Ds with the SEC since 2020, most recently Jun 2024 ($51.4M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Interius BioTherapeutics
Funding rounds
4 roundsAbout Interius BioTherapeutics
Developer of a genetic medicines precision delivery platform intended to treat hematologic malignancies. The company's platform develops chimeric antigen receptor T cells directly in vivo, bypassing the need for ex vivo cell manipulations and the potentially toxic preconditioning chemotherapy required for standard CAR T-cell treatments, enabling clinicians to provide therapies to treat an array of challenging diseases for patients.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2019
- Employees
- 52
- Website
- interiusbio.com/
- Ownership
- Privately Held (backing)
Interius BioTherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Interius BioTherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Interius BioTherapeutics in its N-PORT filings yet. We sweep new filings monthly.